title: Elimination of imatinib mesylate and its metabolite N-desmethyl-imatinib.
authors.forename: Martin
authors.initials: M
authors.lastname: Bornhäuser
authors.forename: Stefan
authors.initials: S
authors.lastname: Pursche
authors.forename: Malte
authors.initials: M
authors.lastname: Bonin
authors.forename: Jens
authors.initials: J
authors.lastname: Freiberg-Richter
authors.forename: Andreas
authors.initials: A
authors.lastname: Jenke
authors.forename: Thomas
authors.initials: T
authors.lastname: Illmer
authors.forename: Gerhard
authors.initials: G
authors.lastname: Ehninger
authors.forename: Eberhard
authors.initials: E
authors.lastname: Schleyer
mesh_terms: D000970:Antineoplastic Agents / Q000737:chemistry* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy*; D010879:Piperazines / Q000737:chemistry* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000737:chemistry* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D014018:Tissue Distribution
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases